The North America Stem Cell Umbilical Cord Blood Market is estimated to witness a rise in revenue from US$ 1,527.5 Mn in 2021 to US$ 3,828.3 Mn by 2027. The market is registering a CAGR of 16.5% during the forecast period 2022-2027. Stem cell therapy is one of the types of therapies that are being introduced for the betterment and advancement of healthcare sector and people around the world are turning to them and rejecting traditional regimens of drugs and hospital visits. The most common genetic disease treated is Severe Combined Immune Deficiency (SCID) followed by aplastic anemia. Cord blood has been extensively used for treatment of genetic diseases. It is one of three sources of blood stem cells that can repopulate a patient’s blood and immune system. Furthermore, the use of allogeneic hematopoietic stem cells (HSCs) to treat genetic blood cell diseases has become a clinical standard. Allogeneic hematopoietic cell transplantation (HCT) therapy is increasingly used for many patients with hematologic malignancies and other type of marrow failure or immune system disorders.
The major factor responsible for the growth of the North America stem cell umbilical cord blood market includes increasing demand of genetic testing, fertility and reproduction assisted services and rise in spending capacity and suitable payment plans. The rising prevalence of genetic diseases such as autoimmune disease, cancer and diabetes has majorly augmented the demand for genetic testing in North America. Moreover, rise in spending capacity, suitable payment plans and significant increase in public investment for stem cell research further boost the market growth. Furthermore, the adoption of artificial intelligence and data science has provided ample of expansion opportunities to the market players. However, there are various ethical and legal issues related to cord blood stem cell research associated with the embryo. Also, identifiers or labeling of cord blood units provides yet another set of legal and ethical challenges in the marketplace.
Diseases treated by cord blood transfusion
Cancer
Blood disorders
Immune disorders
Metabolic disorders
Report Summary
The study of the North America Stem Cell Umbilical Cord Blood Market considers various market determinants, industry value chain analysis and competitor analysis of the market. The report discusses the analysis of the stem cell umbilical cord blood industry for the period 2017-2027, where the base year is 2021 and the forecast period is 2022-2027. The report provides a detailed analysis of the North America Stem Cell Umbilical Cord Blood Market across 11 Chapters and 167 pages. The report includes data presentation across 19 tables and 43 statistical figures.
The report provides PESTLE analysis, which is a tool to examine the external market environment factors that have an impact on the industry. The PESTLE analysis examines the Political, Economic, Social, Technological, Environmental and Legal factors in the external environment. Thus, sufficiently examining the threats and weaknesses of the industry. The research report also provides Porter’s five forces analysis wherein bargaining power of buyers is low and competitive rivalry is high.
The subsequent section provides details of the market analysis based on different segments such as therapeutics, applications and country. The report includes detailed study of value chain of the industry. It includes laboratory requirements, processing and storage, distribution and end users. The report also covers extensively about the key competitors in the market for stem cell umbilical cord blood.
Impact of COVID-19 on North America Stem Cell Umbilical Cord Blood Market
COVID‐19 impacted industries with major hinderances in their businesses due to global shutdown activities to prevent the spread of virus. However, several markets particularly related to healthcare has flourished over time. In the past few years, stem cells have been proven to be an effective method to treat pulmonary disorders, including COVID-19. In addition, the prevailing scenario of COVID-19 is one of the factors driving the growth of the stem cell umbilical cord blood market in various regions. Stem cell therapy can be considered as a potential approach for the treatment of COVID-19 in the future. For instance, Lineage Cell Therapeutics received a grant of US$ 5 million from the California Institute for Regenerative Medicine (CIRM) to support the use of its allogeneic dendritic cell therapy for the development of a potential vaccine against SARS-CoV-2.
Key Takeaways from the North America Stem Cell Umbilical Cord Blood Market Report
Company Profile
Competitive Landscape
The key players in the North America Stem Cell Umbilical Cord Blood Market are Advanced Cell Technology, Inc., Americord Registry LLC, Athersys, Inc., California Stem Cell (CSC), CBR Systems, Inc., China Cord Blood Corporation (CCBC), Cord Blood America, Inc. (CBAI), Cordlife Group Limited, Cryo-Cell International, Inc., Cryoviva India, Sangamo Therapeutics, Inc., ExCellThera Inc., Geron Corporation, LifeCell International Pvt. Ltd., MEDIPOST, Magenta Therapeutics, Mesoblast Ltd, Cryo-Save, Opexa Therapeutics, Inc., Regrow Biosciences Pvt Ltd., Smart Cells International Ltd., Tacitus Therapeutics, Sino Biological and Teva Pharmaceuticals among others. Through extensive research, it is found that big players have adopted various competitive strategies such as mergers & acquisitions in order to have a grip of emerging market. Furthermore, leading companies are expanding their geographical boundaries by acquiring small brands and domestic companies.
Segmentation Overview
North America Stem Cell Umbilical Cord Blood Market is segmented based on therapeutics, applications and country. The industry trends in the stem cell umbilical cord blood market are sub-divided into different categories in order to get a holistic view of the North America marketplace.
Following are the different segments of the North America Stem Cell Umbilical Cord Blood Market:
By Therapeutics segment of the North America Stem Cell Umbilical Cord Blood Market is sub-segmented into:
By Applications segment of the North America Stem Cell Umbilical Cord Blood Market is sub-segmented into:
By Country segment of the North America Stem Cell Umbilical Cord Blood Market is sub-segmented into:
Stem cell therapy is one of the types of therapies that are being introduced for the betterment and advancement of healthcare sector and people around the world are turning to them and rejecting traditional regimens of drugs and hospital visits.
Stem cell therapy is an expensive therapy as stem cell field is still highly specialized and has not been adopted by the mainstream and insurance companies. Additionally, there are very few sources for stem cells, labs that are equipped to process stem cells and reputable clinics that provide the treatments.
The North America stem cell umbilical cord blood market is studied from 2017-2027.
The different segmentations of the North America stem cell umbilical cord blood market are therapeutics, applications and country.
The adoption of artificial intelligence and data science provides a lucrative growth opportunity in the North America stem cell umbilical cord blood market.
The U.S. held the major share in terms of revenue, in the North America stem cell umbilical cord blood market in 2021.
The growth rate of the North America stem cell umbilical cord blood market is 16.5%, with an estimated value of US$ 3,828.3 Million by 2027.
Factors such as increasing demand of genetic testing, fertility and reproduction assisted services and rise in spending capacity and suitable payment plans drives the growth in the North America stem cell umbilical cord blood market during forecast period.
Legal and ethical issues during collections is a restraining factor which inhibits the growth of the market during the forecast period.
The immune disorders segment is anticipated to grow at the highest CAGR during the forecast period owing to high prevalence of inherited immune system disorders in North America.
Cord blood has huge potential to treat chronic diseases such as cancer, diabetes, blood and immune diseases. Also, it has been extensively used for treatment of genetic diseases.
The key players operating in the market include Advanced Cell Technology, Inc., Americord Registry LLC, Athersys, Inc., California Stem Cell (CSC), CBR Systems, Inc., LifeCell International Pvt. Ltd., MEDIPOST, Magenta Therapeutics, Mesoblast Ltd, Cryo-Save, Opexa Therapeutics, Inc., Regrow Biosciences Pvt Ltd., Smart Cells International Ltd., Tacitus Therapeutics, Sino Biological and Teva Pharmaceuticals among others.
Features | Type of License | |||
 Single User |   Multi User |  Corporate | ||
| e-Access | ✓ | ✓ | ✓ | |
User Sharing | 1 User Only | 2-6 Users | Unlimited within Company/Enterprise | |
⨉ | ⨉ | ✓ | ||
Free Customization | Up To 30 hrs work | Up To 60 hrs work | Up To 80 hrs work | |
Deliverable |
| ✓ | ✓ | ✓ |
| ⨉ | ✓ | ✓ | |
| ⨉ | ⨉ | ✓ | |
Analyst Support | 4 Month Post purchase | 7 Month Post purchase | One Year Post purchase | |
Free Report update in next update cycle | ⨉ | ⨉ | ✓ | |
Free Industry Update (Within 180 days) | ⨉ | ⨉ | ✓ | |
Benefit | Up to 20% off on next purchase | Up to 30% off on next purchase | Up to 40% off on next purchase | |
| Report ID: AA0422200 
